A recent report by Glass et al. (8) confirms the protective effect of disease-specific human milk antibodies against gastrointestinal infections in breast-fed infants. Unfortunately, bottle-fed and weaned infants, who do not receive these antibodies and the other host resistance factors in human milk (9) , may have increased susceptibility to life-threatening gastrointestinal infections (2, 18, 22, 25) . These infants could, at least theoretically, be protected by an infant formula fortified with antibodies. To be effective, these antibodies must resist digestion, thereby remaining functionally active in the gastrointestinal tract. Furthermore, the antibodies must be directed against a variety of potential gastrointestinal pathogens (12) . Petersen and Campbell (21) first suggested that orally administered bovine colostrum could provide passive immune protection for humans. Subsequently, Fernandez et al. (5) successfully used lyophilized bovine colostrum to treat infants with intractable diarrhea. Mietens et al. (20) had similar results in infants with Escherichia coli gastroenteritis treated with bovine colostral whey (lactoserum) containing specific anti-E. coli immunoglobulin G class 1 (IgGl) antibodies. These anti-E. coli antibodies retained their immunological activity after passage through the gastrointestinal tracts of infants (13) . The bovine colostral whey used by these investigators (5, 12, 13, 20) may, however, have contained other host resistance factors that could have affected the infant diarrhea (24) . Moreover, bovine colostrum contains a trypsin inhibitor that may have protected the bovine immunoglobulins from proteolysis (23) .
In this report, we present evidence that isolated bovine colostral anti-cholera enterotoxin antibodies resist in vitro inactivation by pepsin and trypsin and remain immunologically and functionally active against cholera enterotoxin in the gastrointestinal tracts of infant and adult rabbits. ,ug of CT in 10 ml of saline. Pooled colostrum was collected at calving and was stored at -20°C until ready for processing. We obtained control colostrum from cows that had not been immunized.
Immunoglobulin preparation. We removed the fat from anti-CT and control colostrum by centrifugation (14,000 rpm at 4°C, JA-21 rotor, Beckman Instruments, Inc., Irving, Calif.). Casein was precipitated from whey proteins by the addition of rennin (2 mg/liter; Sigma Chemical Co., St. Louis, Mo.) and calcium carbonate (4 g/liter), followed by incubation at 30°C until the curd formed. The bovine colostral immunoglobulin fraction (BCI) was separated from the other whey proteins by three repetitive precipitations of the immunoglobulins with saturated ammonium sulfate. For each precipitation, saturated ammonium sulfate was added to the BCI in a ratio of 35 ml of saturated ammonium sulfate to 65 ml of BCI. The final immunoglobulin pellet was suspended in and dialyzed against borate-buffered saline, pH 8.4 (BBS) (6) at 4°C until it was free of detectable sulfate ions (no detectable precipitate formed after addition of a few drops of 10 g of BaCl2 per deciliter).
Immunochemical and biological analyses. Bovine immunoglobulins (i.e., IgGl, IgG2, IgA, and IgM) were quantified with radial immunodiffusion kits (Miles Laboratories, Inc., Elkhart, Ind.). We characterized the anti-CT BCI by ionexchange and affinity chromatography, anti-CT radioimmunoassay, rabbit ileal loop assay (15, 26), and quantitative precipitation (11) .
(i) Ion-exchange chromatography. Anti-CT BCI (160 to 170 mg of total protein) (17) was applied to a DEAE-cellulose column (31 by 1.6 cm; DE-52, Whatman Ltd., Maidstone, Kent, United Kingdom). The immunoglobulins were eluted with a 0.017 to 0.2 M sodium phosphate buffer linear gradient (pH 8.0) at 4°C. We operated the column at 18 ml/cm2 per h, collected 2-ml fractions, and monitored protein concentration spectrophotometrically (280 nm). We lyophilized all protein peaks and redissolved them in BBS. Two-dimensional gel diffusion with rabbit anti-bovine IgGl, IgG2, IgA, and IgM antisera (Miles Laboratories) identified bovine immunoglobulins.
(ii) Affinity chromatography. We coupled 5 mg of CT to 3 g of cyanogen bromide-activated Sepharose 4-B beads as instructed by the bead supplier (Sigma). To obtain anti-CT affinity-purified bovine colostral antibodies, we incubated 9 BOVINE COLOSTRAL IgGl ANTIBODY 475 Unadsorbed immunoglobulins were washed from the affinity beads with 150 ml of BBS. Specific anti-CT antibodies were eluted from the beads with 20 ml of glycine-hydrochloride buffer (0.2 M; pH 2.0). We then dialyzed the anti-CT affinity eluate overnight at 4°C against 12 liters of BBS.
(iii) Anti-CT radioimmunoassay (RIA). We isolated the A subunit of CT (16) and labeled it with 125I by the chloramine T method (10 Ion-exchange chromatography separated the anti-CT BCI into three peaks (Fig. 1) . The first peak is predominantly IgG2, whereas the second peak contains IgGl with some IgA and IgM. The third peak is mainly IgM with some IgGl. We evaluated each peak for precipitating antibody to CT and found anti-CT antibody in the early portion of the second peak, suggesting that our anti-CT was an IgGl or an IgA antibody or both. In the anti-CT eluate from the affinity column, only IgGl was quantifiable (0.7 mg/ml). Precipitin lines to IgA and IgG2 were just detectable but could not be quantified by radial immunodiffusion.
Biological activity of anti-CT colostral preparations. The maximum dilutions of anti-CT bovine colostral whey, anti-CT BCI, and anti-CT affinity eluate that completely neutral- In vitro and in vivo proteolysis of anti-CT. After exposure to trypsin at an enzyme/substrate ratio of 1:100 and to pepsin (1:20) at pH 2.0 or 4.0, anti-CT BCI retained activity against CT in the rabbit ileal loop assay. Fifty microliters of both pepsin digests and the 1:100 trypsin digest completely neutralized 100 ng of CT. Fifty microliters of the 1:20 trypsin digest of anti-CT immunoglobulins neutralized only 48 + 25% of the fluid secretion induced by 100 ng of CT. The inactivated enzymes in buffer had no neutralizing activity in the ileal loop assay.
Six of seven adult rabbits fed anti-CT whey had sufficient anti-CT activity in 50 1.l of reconstituted cecal fluid to neutralize completely 100 ng of CT in the rabbit ileal loop assay. Only two of seven control whey-fed animals and one of seven saline-fed animals had 100% neutralizing activity in their cecal extracts (P = 0.05 by Fisher exact test). Cecal extracts from anti-CT whey-fed animals exhibited a mean (+ Mortality of infant rabbit feeding groups 18 h after direct intestinal injection of 100 ng of CT. Before CT injection, each group received three feedings over 24 h (total, 9 ml per animal) of anti-CT bovine colostral immunoglobulins (immune BCIs), nonimmune BCIs, or D5W. Animals selected randomly from each feeding group were injected with saline in lieu of CT and served as sham controls. standard deviation) anti-CT antiody content of 5.7 ± 2.0 ,ug/ ml as determined by anti-CT RIA. Neither the non-immunefed nor the D5W-fed animals had CT binding activity in their cecal extracts as determined by RIA. The bovine immunoglobulin content of the cecal extracts from rabbits fed anti-CT or control colostrum contained 0 to 0.56 mg of IgGl and 0 to 4.2 mg of IgA per ml.
In vivo protection. After dialysis against D5W, the immune (anti-CT) BCI preparation had 62.4 mg of IgGl and 2.7 mg of IgA per ml, whereas the control immunoglobulins (nonimmune BCIs) contained 38.4 and 8.0 mg/ml, respectively. When we examined the gross mortality and FAI of each feeding group, animals fed immune BCI were protected from the adverse effects of CT ( Fig. 2 and 3) . The mortality and FAI data of the immune BCI group were statistically the same as the data in the sham-operated, saline-injected control group. The mortality of immune BCI-fed animals (14.3%) was significantly less than that of the nonimmune BCI-or D5W-fed animals (66.7 and 80%, respectively [P < 0.01]; Fig. 2 ). Too few toxin-injected control animals (nonimmune-fed and D5W-fed) survived to allow meaningful comparison of group FAIs; however, when survivors of these control groups were combined, they exhibited an FAI significantly greater than that of either the immune BCI-fed or sham control animals (P < 0.01; Fig. 3) . DISCUSSION In this report, we demonstrate that pregnant cows immunized with cholera enterotoxin produce primarily an IgGl antibody that is secreted in large quantities into the colostrum. This antibody represents approximately 3% of the total colostral IgGl content. After in vitro exposure to trypsin at an enzyme/substrate ratio of 1:100, these anti-CT IgGl antibodies still retained their ability to neutralize completely 100 ng of CT in the ileal loop assay. In vitro exposure of anti-CT BCI ito trypsin at a higher ratio of enzyme to immunoglobulin resulted in a 50% decrease in neutralizing activity against CT. Exposure of anti-CT antibody to pepsin at pH 4.0 and 2.0 had no appreciable effect on anti-CT neutralizing activity in the ileal loop assay. Furthermore, a protective concentration of anti-CT antibodies could be found in the cecal contents of adult rabbits fed anti-CT BCI. When anti-CT antibodies were fed to infant rabbits, the (12, 13, 20 The anti-CT immunoglobulin fraction may have contained some secretory IgA antibody with anti-enterotoxin activity. These secretory IgA anti-CT antibodies would also resist proteolysis. They could account for the presence of anti-CT activity and the apparently low concentration of bovine IgGl in the ceca of rabbits fed colostral whey. Nevertheless, the amount of IgA found in the affinity-purified fraction of the anti-CT immunoglobulins was very low; therefore, we believe that specific anti-CT secretory IgA antibodies contributed very little to the rabbit cecal anti-CT activity.
We have not evaluated the anti-CT BCI for the presence of bovine colostral trypsin inhibitor or other host resistance factors such as lactoperoxidase, lactoferrin, and lysozyme. Trace quantities of these proteins may be present, although it is unlikely that these proteins would be precipitated by 35% saturated ammonium sulfate. In addition, it seems quite unlikely that such proteins would have adsorbed to the CTSepharose beads or eluted from the DEAE-cellulose column in the same fractions as the anti-CT immunoglobulins. Moreover, the total protein content of BCI measured by the method of Lowry et al. (17) is very similar to the total immunoglobulin content measured by quantitative radial immunodiffusion (19) .
Our findings are consistent with the results of earlier investigators (12, 13, 20, 27, 18) and add information regarding the activity of a specific bovine colostral antibody directed against the enterotoxin of Vibrio cholerae. Our results suggest that specific bovine colostral antibodies, administered orally, may be a means of providing passive immune protection of infants at risk for enteric disease. We have not yet determined the resistance of these bovine colostral anti-CT antibodies to passage through the human infant gastrointestinal tract, or the ability of these antibodies to neutralize toxin produced by viable organisms. Furthermore, we have not compared anti-CT BCIs with established antitoxin antibody standards.
